1 Week left before the #ScripAwards2018 at the Hilton on Park Lane, London! Join us for an evening of glitz, glam, good food and networking. Last few tables remaining - book yours today! bit.ly/2DMxaiP

🎥 H. Lundbeck CEO and president Deborah Dunsire talks to Jo Shorthouse about what drew her to the pharma company, which specializes in neurological disorders. Watch #BIOEurope interview >> spr.ly/6010EDm4y

🎥 Jo Shorthouse to RedHill Biopharma COO, Gilead Raday, on the company's novel antibiotic approach to #CrohnsDisease. Watch #BIOEurope interview >> spr.ly/6019EDmNd

Per Norlen, CEO of Alligator Bioscience, tells Scrip, Citeline Commercial's Jo Shorthouse about the recent addition to the pipeline, and the next big milestones for the company. Watch #BIOEurope interview >> spr.ly/6010EDm7g

🎥 Jo Shorthouse talks to RedHill Biopharma COO, Gilead Raday, on the company's novel antibiotic approach to #CrohnsDisease. Watch #BIOEurope interview >> spr.ly/6016EDm4s

Per Norlen, CEO of Alligator Bioscience, tells Scrip, Citeline Commercial's Jo Shorthouse about the recent addition to the pipeline, and the next big milestones for the company. Watch #BIOEurope interview >> spr.ly/6014EDm74

It's finally here! Time to get those glad rags on and join us tonight at the Hilton, Park Lane for the #ScripAwards2018! We look forward to seeing you tonight!

After careful reflection, I will not be supporting the Government on the EU Withdrawal Agreement. As such, I have tended my resignation as Universities & Science Minister – read more on my Facebook page: facebook.com/20438821971510…

When reflecting on the licensing deals inked this year by biotech behemoth Genentech, two really stand out. At #BIOEurope Jo Shorthouse sits down with Don O’Sullivan, the company's Head of Immunology and Infectious Disease Business Development. spr.ly/6019E1Ffx

And here’s another big one for #JPM19, $LLY to buy $LOXO for $8bn.

Wow. José Baselga, who quit Memorial Sloan Kettering after failing to disclose financial conflicts of interests, to head up R&D oncology at #AstraZeneca

Ian Hudson chairing a session at #DIAEurope2019 today. This year is Hudson’s last appearance at DIA Europe as head of MHRAgovuk. He’s stepping down as chief exec of UK agency in September.

I am delighted to announce that from October I will be the new Master of Trinity College. It has truly been an honour to be the first female Chief Medical Officer and I will be working relentlessly until I step down at the end of September gov.uk/government/new…

Simon Moroney, @MorphoSys CEO stalwart is to retire by middle of next year. He talked to me about his hopes to inspire small EU #biotech and reacts to the Darzalex IP loss.

Peter McNaughton of King's College London talked to me yesterday about the ground breaking science behind a new class of analgesics, #Merck pretty impressed too.

Akari Therapeutics $AKTX @AkariTx skyrockets as #FDA clears #pivotal trial for dual-action #Coversin in pediatric #TMA bioworld.com/content/akari-…

What Brexit Effect? UK Biotech Start-Ups Reach Record Numbers bit.ly/2FhQYsS #PharmaScrip

16% jump in Daiichi Sankyo's share price this morning in Tokyo reflects size, significance of deal #pharma #biotech #cancer #daiichisankyo #astrazeneca Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset scrip.pharmaintelligence.informa.com/articles/2019/…

Sydney Brenner: Molecular biology pioneer dies - a giant has left the stage bbc.co.uk/news/science-e…

$NVS CEO tells me Cosentyx overtaken Humira in PsA/AS in the USA, had Q1 sales $791m, up 41%, Entresto up 85% to $357m